ADELMAN DANIEL C MD 4
4 · Aimmune Therapeutics, Inc. · Filed Jan 3, 2020
Insider Transaction Report
Form 4
ADELMAN DANIEL C MD
Chief Medical Officer
Transactions
- Sale
Common Stock, $0.0001 par value
2020-01-02$35.00/sh−20,000$700,038→ 21,250 total - Exercise/Conversion
Stock Option (right to buy)
2020-01-02−20,000→ 70,000 totalExercise: $19.63Exp: 2027-02-24→ Common Stock (20,000 underlying) - Exercise/Conversion
Common Stock, $0.0001 par value
2020-01-02$19.63/sh+20,000$392,600→ 41,250 total
Footnotes (5)
- [F1]The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]Includes 11,875 restricted stock units ("RSUs") which will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
- [F3]Includes 9,375 RSUs which will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
- [F4]Represents the weighted average sale price for the entire number of shares sold. The sale prices range from $34.99 to $35.04 per share. Information on the actual numbers of shares sold at each sale price can be obtain from the Issuer upon request.
- [F5]The shares subject to the option will vest and become exercisable as to one-forty-eighth (1/48th) of the total number of shares subject to the option in successive, equal monthly installments measured from February 24, 2017, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.